Supported by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly.
Phase 2 of the ‘AIM-PD’ study was a proof of concept study and involved 20 people with the genetic form of Parkinson’s over a 24 month period and was led by Professor Anthony Schapira at the Royal Free Hospital, London.
We are now looking to support Professor Schapira as he learns more about ambroxol’s safety and ability to penetrate the blood brain barrier at dose levels that are safe and effective in people with Parkinson’s.
How helpful was this content?
/ 5. Vote count:
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?